Takahashi Y, Arai M, Fukutake K
Department of Clinical Pathology, Tokyo Medical College, Japan.
Rinsho Byori. 1996 May;44(5):449-55.
Factor VIII neutralizing antibody (factor VIII inhibitor) sometimes develops in the patients with hemophilia A who are treated with factor VIII concentrates and more rarely in non-hemophilic individuals as auto antibody. Factor VIII inhibitor titer is most commonly measured by Bethesda method in which the sample is mixed with normal pooled plasma as a source of factor VIII for 2-hour incubation followed by measurement of residual factor VIII activity. Because of its simplicity and accessibility of normal pooled plasma, Bethesda method is widely used in clinical laboratories. However, the reproducibility of the assay is not generally considered to be satisfactory and measurement of inhibitor units varies among laboratories. In the present study, the factors which affect the measurement of Bethesda method were assessed. The reproducibility of Factor VIII activity showed better in a factor VIII dose dependent manner and varies according to clotting threshold of the sample that is analyzed by an automated coagulation equipment and a desktop computer. The reproducibility of inhibitor measurement was worse in the inter-assay than in the intra-assay. The assay fluctuation of the measurement of lower inhibitor units tends to be more evident when the sample of 0.39 to 2.39 BU/ml were tested. The factor VIII content in the normal pooled plasma did not affect the measurement of factor VIII inhibitor units in the range of 0.8 to 1.2 U/ml. The buffers retained factor VIII in the control sample during the 2-hour incubation better in the order of imidazole buffer, bernard buffer, Tris-HCl buffer and saline.
血友病A患者在接受凝血因子Ⅷ浓缩物治疗时,有时会产生凝血因子Ⅷ中和抗体(凝血因子Ⅷ抑制物),在非血友病个体中作为自身抗体产生的情况则更为罕见。凝血因子Ⅷ抑制物滴度最常用贝塞斯达法测定,即把样本与作为凝血因子Ⅷ来源的正常混合血浆混合孵育2小时,然后测定残余凝血因子Ⅷ活性。由于该方法简便且可获得正常混合血浆,贝塞斯达法在临床实验室中被广泛应用。然而,该检测方法的可重复性一般认为并不令人满意,不同实验室对抑制物单位的测量结果存在差异。在本研究中,对影响贝塞斯达法测量结果的因素进行了评估。凝血因子Ⅷ活性的可重复性呈凝血因子Ⅷ剂量依赖性,且根据自动凝血设备和台式计算机分析的样本凝血阈值而有所不同。抑制物测量的可重复性在批间比批内更差。当检测0.39至2.39 BU/ml的样本时,较低抑制物单位测量的检测波动往往更为明显。正常混合血浆中凝血因子Ⅷ的含量在0.8至1.2 U/ml范围内不影响凝血因子Ⅷ抑制物单位的测量。在2小时孵育期间,缓冲液按咪唑缓冲液、伯纳德缓冲液、Tris-HCl缓冲液和生理盐水的顺序,能更好地保留对照样本中的凝血因子Ⅷ。